## AEE: Ameren Corporation - XLU: Utilities

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%); PEG 2.38 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($96.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Finviz | 20260105T040754 | Somewhat-Bullish | Relevance: 100%
- UBS has maintained a Buy rating on Ameren Corporation (AEE) while slightly reducing its price objective to $115 from $121. Despite this, Ameren revised its long-term EPS growth guidance to 6% to 8% compound annual rate from 2025 through 2029, driven partly by expected data center growth. The company, a regulated utility in Illinois and Missouri, has seen its stock rise by 12.21% YTD as of December 31, 2025, with analysts recognizing its strong investment opportunities and management's ability to navigate regulatory challenges.

**2. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Insider Monkey | 20260104T224229 | Somewhat-Bullish | Relevance: 100%
- UBS has reiterated its Buy rating on Ameren Corporation (AEE) but adjusted its price target to $115 from $121, while Morgan Stanley maintained an Equal Weight rating and lowered its price target to $103. Ameren revised its long-term EPS growth guidance to a 6% to 8% compound annual rate from 2025 through 2029, with predicted 2026 EPS between $5.25 and $5.45. The company operates as a regulated utility in Illinois and Missouri, with Morningstar highlighting improved regulations in Missouri as beneficial for investment opportunities.

**3. A Look At Ameren (AEE) Valuation As New Earnings Growth Outlook And Analyst Targets Emerge**
- Source: Simply Wall Street | 20260105T112814 | Bullish | Relevance: 100%
- Ameren (AEE) has provided new long-term earnings growth guidance of 6% to 8% annually from 2025 through 2029, alongside updated analyst views. The stock is currently trading at $100.86, representing a 10.66% discount to the average analyst price target of $111.62, which is supported by expectations of expanding regulated rate base and constructive regulatory relationships. However, a Discounted Cash Flow (DCF) model suggests Ameren might be overvalued with a fair value of $88.10, highlighting a divergence in valuation perspectives.

**4. UBS Keeps Buy Rating on Ameren Corporation (AEE)**
- Source: Yahoo! Finance Canada | 20260104T173000 | Somewhat-Bullish | Relevance: 100%
- UBS has maintained its Buy rating on Ameren Corporation (AEE) but adjusted its price objective to $115 from $121. The utility company reported revised long-term EPS growth guidance of 6% to 8% annually from 2025 through 2029, with projected 2026 EPS between $5.25 and $5.45. This comes as data centers are expected to drive utility performance, and while regulations in Illinois present challenges, management has effectively navigated them.

**5. SteelPeak Wealth LLC Buys New Shares in Ameren Corporation $AEE**
- Source: MarketBeat | 20260103T121146 | Somewhat-Bullish | Relevance: 100%
- SteelPeak Wealth LLC recently purchased 29,716 shares of Ameren Corporation (NYSE:AEE), valued at approximately $3.1 million, in Q3, contributing to the 79.09% institutional ownership of the stock. Ameren exceeded Q3 earnings estimates and provided a positive FY2026 EPS guidance, while analysts rate it a "Moderate Buy" with a $108.80 consensus price target and a 2.8% dividend yield. Despite a recent sale by CFO Michael L. Moehn, insider ownership remains at 0.42% as other institutional investors have also increased their stakes.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | UBS | $115 | $121 | -5% |
| 2025-12-12 | Keybanc | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | UBS | main | Buy |
| 2025-12-12 | Keybanc | down | Sector Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 7 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 13.0% (-1.2%)
- Price (T.Rowe) Assoc: 10.6% (-0.8%)
- Blackrock Inc.: 8.0% (+1.5%)
- T. Rowe Price Invest: 5.7% (+8.1%)
- State Street Corpora: 5.2% (+2.4%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.38 elevated, pricing in significant growth expectations. Forward P/E 18.7x stretched relative to 6% growth. Quality metrics strong (margin 16%). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.9B |
| Beta | 0.59 |
| 52W Range | $86.81 - $106.73 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.38 |
| Forward P/E | 18.7 |
| Current P/E | 19.8 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.1% (minimal 5-day change). Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). Below SMA200 (1.00x), long-term trend not supportive. RSI neutral at 46. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.08% (CS: 38) | Neutral |
| RSI_14 | 46.0 | Neutral |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 0.978x | Below |
| vs SMA200 | 0.998x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.62
- **Stop Loss:** $96.66 (3.0% risk)
- **Target:** $102.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 388
- **Position Value:** $38,652.56
- **Portfolio %:** 38.65%
- **Risk Dollars:** $1,150.00
- **Risk Per Trade:** 1.15%
- **Modifiers:** L1 115% | L2 100% | Combined 1.15x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $0.79)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.11 | $2.35 | +11.4% |
| 2025Q2 | $1.00 | $1.01 | +1.4% |
| 2025Q1 | $1.04 | $1.07 | +2.8% |
| 2024Q4 | $0.80 | $0.77 | -3.2% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*